By Dr. Elica Kyoseva (Boehringer Ingelheim).
In this talk, I will showcase in some technical details a use case from Boehringer Ingelheim's pharmaceutical pipeline that can be improved with the help of quantum computing. We focus on NISQ quantum devices and show how quantum computers can be used for calculating large scale drug-ligand interaction energies.
Ref: Towards the simulation of large scale protein-ligand interactions on NISQ quantum computer, accepted in Chemical Science [ Ссылка ]
Dr Elica Kyoseva is a Quantum Computing Scientist at the German pharmaceutical company Boehringer Ingelheim, where she is working on advancing the drug discovery process through quantum computing. Her main focus is on the extremely precise modelling of molecular systems that will enable new ways to discover drugs and will thus contribute to the global medical progress in the future.
Elica has more than 15 years of experience in the field of quantum computing and has held leadership positions in academia, the private investments field, and industry of three continents - Europe, Asia and North America. Prior to joining BI, Elica was an MIT fellow and an entrepeneur in residence in a venture capital firm. Originally from Bulgaria, Elica currently lives in Israel.
Webinar hosted by Universidad Politécnica de Madrid, as part of its Master in Quantum Computing Technology ([ Ссылка ])
